SCHEMBL4073398

SCHEMBL4073398

CNC(=S)NCc1ccc2ccn(C3CCN(C(F)Cc4ccccc4)CC3)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
MAPT P10636 5/20 0.39
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 2/20 0.37
ALOX12 P18054 4/20 0.36
LMNA P02545 3/20 0.36
PKM P14618 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
PLA2G1B P04054 2/20 0.35
ATG4B Q9Y4P1 2/20 0.35
DRD2 P14416 1/20 0.35
SLC6A4 P31645 1/20 0.35
ALPL P05186 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076932 0.87 HTR1A (0.39) DRD2SLC6A4HTR1AHTR1DHTR1B
SCHEMBL5871549 0.85 HTT (0.39) ALDH1A1KMT2AMEN1HPGDLMNA
SCHEMBL5871626 0.84 HTT (0.39) ALDH1A1KMT2AMEN1HPGDGAA
SCHEMBL5871563 0.84 HTT (0.39) ALDH1A1KMT2AMEN1HPGDGAA
SCHEMBL4081920 0.83 SCD (0.40) DRD2SLC6A4HTR1AHTR1DHTR1B
SCHEMBL5871664 0.83 HTT (0.38) ALDH1A1KMT2AMEN1HPGDLMNA
SCHEMBL5871737 0.82 SCD (0.45) DRD2SLC6A4HTR1AHTR1DHTR1B
SCHEMBL6619909 0.80 HTR1A (0.46) LMNADRD2SLC6A4HTR1AHTR1D
SCHEMBL5871341 0.80 DRD2 (0.39) DRD2SLC6A4HTR1AHTR1DHTR1B
SCHEMBL5871706 0.80 TACR1 (0.41) MAPTKMT2AMEN1DRD2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541371-B2 Method for treating a motor neuron disease EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US claimed
US-20080027039-A1 Method for treating a motor neuron disease EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-31 US claimed
US-7541371-B2 Method for treating a motor neuron disease EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20080027039-A1 Method for treating a motor neuron disease EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027039-A1 Method for treating a motor neuron disease SMN1; SMN2, NLN, SLC18A2 ALDH1A1 1039/4885MAPT 110/4885KMT2A 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.